论文部分内容阅读
目的:了解含顺铂(DDP)的方案治疗鼻咽癌后引起骨髓抑制的情况,为临床上对其预防和治疗提供依据。方法:对接受含DDP方案治疗的鼻咽癌患者的出院病历进行回顾性调查,记录治疗方案、治疗前后的外周血常规等指标,并进行统计、分析。结果:在使用含DDP方案治疗的299例鼻咽癌患者中,治疗后出现骨髓抑制的有205例(占68.6%),其中Ⅰ～Ⅱ级骨髓抑制为57.2%,Ⅲ～Ⅳ级骨髓抑制为11.4%;42.9%的骨髓抑制患者可治愈,其中Ⅰ、Ⅱ级骨髓抑制的治愈率分别为54.6%、37.8%,Ⅲ、Ⅳ级骨髓抑制的治愈率分别为25.0%、0。结论:含DDP方案治疗鼻咽癌后骨髓抑制的发生率高,严重的骨髓抑制不易恢复。
OBJECTIVE: To understand the situation of myelosuppression induced by cisplatin (DDP) in the treatment of nasopharyngeal carcinoma and provide the basis for its prevention and treatment clinically. Methods: A retrospective investigation was made on the discharge records of patients with nasopharyngeal carcinoma treated with DDP regimen. The treatment regimen and peripheral blood routine before and after treatment were recorded and statistically analyzed. RESULTS: Of the 299 patients with nasopharyngeal carcinoma treated with the DDP regimen, 205 (68.6%) had myelosuppression after treatment, with grade Ⅰ-Ⅱ myelosuppression 57.2% and grade III-IV myelosuppression 11.4%. 42.9% of patients with myelosuppression were cured. The cure rates of grade Ⅰ and Ⅱ myelosuppression were 54.6% and 37.8% respectively. The cure rates of grade Ⅲ and Ⅳ myelosuppression were 25.0% and 0%, respectively. CONCLUSION: The incidence of bone marrow suppression after treatment of nasopharyngeal carcinoma with DDP regimen is high, and severe myelosuppression is not easy to recover.